These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 18071073)

  • 1. Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone.
    Randriamboavonjy V; Pistrosch F; Bölck B; Schwinger RH; Dixit M; Badenhoop K; Cohen RA; Busse R; Fleming I
    Circulation; 2008 Jan; 117(1):52-60. PubMed ID: 18071073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
    Sorrentino SA; Bahlmann FH; Besler C; Müller M; Schulz S; Kirchhoff N; Doerries C; Horváth T; Limbourg A; Limbourg F; Fliser D; Haller H; Drexler H; Landmesser U
    Circulation; 2007 Jul; 116(2):163-73. PubMed ID: 17592079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease.
    Sidhu JS; Cowan D; Tooze JA; Kaski JC
    Am Heart J; 2004 Jun; 147(6):e25. PubMed ID: 15199366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in platelet Ca2+ signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production.
    Schaeffer G; Wascher TC; Kostner GM; Graier WF
    Diabetologia; 1999 Feb; 42(2):167-76. PubMed ID: 10064096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty.
    Wang G; Wei J; Guan Y; Jin N; Mao J; Wang X
    Metabolism; 2005 May; 54(5):590-7. PubMed ID: 15877288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The S1P(2) receptor expressed in human platelets is linked to the RhoA-Rho kinase pathway and is down regulated in type 2 diabetes.
    Randriamboavonjy V; Badenhoop K; Schmidt H; Geisslinger G; Fisslthaler B; Fleming I
    Basic Res Cardiol; 2009 May; 104(3):333-40. PubMed ID: 19139947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet signalling abnormalities in patients with type 2 diabetes mellitus: a review.
    El Haouari M; Rosado JA
    Blood Cells Mol Dis; 2008; 41(1):119-23. PubMed ID: 18387322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.
    Vrablík M; Dobiásová M; Stulc T; Kasalová Z; Dolezalová R; Prázný M; Fait T; Ceska R
    Neuro Endocrinol Lett; 2008 Feb; 29(1):146-50. PubMed ID: 18283261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
    Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
    Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of plasma membrane Ca(2+)ATPase 4b in platelets from hypertensives: a new sign of abnormal thrombopoiesis?
    Dally S; Chaabane C; Corvazier E; Bredoux R; Bobe R; Ftouhi B; Slimane H; Raies A; Enouf J
    Platelets; 2007 Nov; 18(7):543-9. PubMed ID: 17957572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study on the action of vitamin E supplementation on plasminogen activator inhibitor type 1 and platelet nitric oxide production in type 2 diabetic patients.
    Vignini A; Nanetti L; Moroni C; Testa R; Sirolla C; Marra M; Manfrini S; Fumelli D; Marcheselli F; Mazzanti L; Rabini RA
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):15-22. PubMed ID: 17949955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinnamtannin B-1 from bay wood reduces abnormal intracellular Ca2+ homeostasis and platelet hyperaggregability in type 2 diabetes mellitus patients.
    Bouaziz A; Salido S; Linares-Palomino PJ; Sanchez A; Altarejos J; Bartegi A; Salido GM; Rosado JA
    Arch Biochem Biophys; 2007 Jan; 457(2):235-42. PubMed ID: 17118329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
    Duan SZ; Usher MG; Mortensen RM
    Circ Res; 2008 Feb; 102(3):283-94. PubMed ID: 18276926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of uncoupling endothelial nitric oxide synthase on calcium homeostasis in aged porcine endothelial cells.
    Perrier E; Fournet-Bourguignon MP; Royere E; Molez S; Reure H; Lesage L; Gosgnach W; Frapart Y; Boucher JL; Villeneuve N; Vilaine JP
    Cardiovasc Res; 2009 Apr; 82(1):133-42. PubMed ID: 19176602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for iNOS-dependent peroxynitrite production in diabetic platelets.
    Tannous M; Rabini RA; Vignini A; Moretti N; Fumelli P; Zielinski B; Mazzanti L; Mutus B
    Diabetologia; 1999 May; 42(5):539-44. PubMed ID: 10333045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.
    Krag MB; Nielsen S; Guo Z; Pedersen SB; Schmitz O; Christiansen JS; Jørgensen JO
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):452-61. PubMed ID: 18331610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet cNOS activity is reduced in patients with IDDM and NIDDM.
    Martina V; Bruno GA; Trucco F; Zumpano E; Tagliabue M; Di Bisceglie C; Pescarmona G
    Thromb Haemost; 1998 Mar; 79(3):520-2. PubMed ID: 9531033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function.
    Borchert M; Schöndorf T; Lübben G; Forst T; Pfützner A
    Diabetes Technol Ther; 2007 Oct; 9(5):410-20. PubMed ID: 17931049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet PPARgamma activation.
    Khanolkar MP; Morris RH; Thomas AW; Bolusani H; Roberts AW; Geen J; Jackson SK; Evans LM
    Atherosclerosis; 2008 Apr; 197(2):718-24. PubMed ID: 17765245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.